Trials (National Cancer Center Dresden): Revision history

14 December 2025

• curprev 20:3420:34, 14 December 2025‎ Francine talk contribs‎ 47,984 bytes +214‎ No edit summary undo

6 December 2025

• curprev 12:4212:42, 6 December 2025‎ Lucas talk contribs‎ m 47,770 bytes +1,701‎ Update categories. undo

3 December 2025

• curprev 02:4002:40, 3 December 2025‎ Larysse talk contribs‎ 46,069 bytes +49‎ No edit summary undo

2 December 2025

• curprev 14:0014:00, 2 December 2025‎ Lucas talk contribs‎ m 46,020 bytes +90‎ Update categories. undo

4 December 2023

• curprev 12:4812:48, 4 December 2023‎ Francine talk contribs‎ 45,930 bytes +45,930‎ Created page with "{{forpatients}} {{forproviders}} {{forresearchers}} Go back to National Cancer Center Dresden page '''NCTID''': NCT03430843 '''Title''': A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma '''Study Summary''': The purpose of this study is to evaluate the efficacy and safety of tislelizumab as second line treatment in participants with advanced unresectable/metastatic ESC..."